1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sprycel is launched in Japan

 
• By Ian Haydock

Bristol-Myers Squibb's Sprycel (dasatinib) has been launched in Japan. The multi-targeted tyrosine kinase inhibitor is indicated for the treatment of imatinib-resistant Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) in the chronic, accelerated or acute (blast) phases, and Ph+ acute lymphoblastic leukaemia (ALL).

Bristol-Myers Squibb's Sprycel (dasatinib) has been launched in Japan. The multi-targeted tyrosine kinase inhibitor is indicated for the treatment of imatinib-resistant Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) in the chronic, accelerated or acute (blast) phases, and Ph+ acute lymphoblastic leukaemia (ALL).

The market entry follows the product's recent inclusion in the national insurance reimbursement tariff. The 20mg tablet is reimbursed at ¥4,565.20 ($47.80) and the 50mg tablet at ¥10,793.30.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Therapeutic Category

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.